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Fabry disease (α-galactosidase deficiency, OMIM 301500) is an X-
linked lysosomal disorder due to mutations in GLA and characterized by
skin lesions (angiokeratomata), recurrent burning pain (acropar-
aesthesias), corneal clouding, hypohidrosis, cardiac and renal injury
and cerebral ischaemia. Heterozygous females have variable clinical
manifestations [1], and white-cell α-galactosidase activity may be de-
ficient or within the healthy reference range. It has been assumed that
severe disease in females who are heterozygous for an X-linked disorder
is due to unfavourable skewing during Lyonization, so that there is
biassed inactivation of the wild type allele in most tissues [2]. To de-
termine whether preferential X-inactivation affecting the wild type GLA
locus contributes to the pathological manifestations in Fabry hetero-
zygotes, the validated clinical (Mainz) severity score values were
compared with the X-inactivation status in 39 females. Heterozygotes in
whom the inactivated X-chromosome carrying the wild-type parental
GLA allele was dominant, were more severely affected than those
without biassed X-inactivation [3]. These findings support the hy-
pothesis that skewed X-inactivation is a major influence on the severity
of clinical manifestations in Fabry heterozygotes. However, the ques-
tion arises as to why, unlike female heterozygotes in Fabry disease,
obligate heterozygous females in pedigrees affected by the X-linked
Hunter syndrome (Mucopolysaccharidosis type II, OMIM 309900), only
very exceptionally show clinical manifestations [4]. This lysosomal
disease is also due to a deficiency of a soluble matrix enzyme of the
lysosome, iduronate-2-sulphatase (IDS). Affected males have cardio-
vascular, respiratory, musculoskeletal manifestations that are often
associated with progressive neurodegeneration [4]. De Camargo et al.
analyzed clinical signs and symptoms, karyotype, pattern of X-in-
activation, IDS activity, urinary glycosaminoglycan concentrations,
computerized X-ray tomographic scans of abdomen and spine, and
brain magnetic resonance imaging in 18 non-heterozygous and 22
heterozygous females. No difference between these groups, either on
physical examination or spinal radiology, karyotype nor on the X-in-
activation pattern was identified - although plasma and leukocyte IDS
activities were significantly lower in plasma and leukocytes in the
heterozygotes compared with healthy wild-type family members [5].
In the exceptionally rarely affected heterozygous females of Hunter
syndrome, signs and symptoms can arise by distinct mechanisms such
as structural abnormalities of the X-chromosome, homozygosity for
mutant IDS alleles or markedly skewed X-inactivation that favours the
X-chromosome bearing wild-type IDS allele [6]. All females with clin-
ical manifestations of Hunter syndrome merit thorough investigation
including karyotyping, analysis of X-inactivation pattern and determi-
nation of iduronate sulphatase activity. Pedigree analysis is mandatory,
since as in Fabry disease, homozygosity can also be the cause of Hunter
syndrome in a female [6].
Now the question arises why in Hunter syndrome (with a few ex-
ceptions) female heterozygotes are asymptomatic carriers and in Fabry
disease heterozygous females often show clinical manfestations - albeit
to a variable degree. One explanation is suggested by the results of cell
culture experiments carried out by Fuller and co-workers [7]. Under the
assumption that cross-correction of enzyme activity in vivo is ineffective
in Fabry heterozygotes, the authors analyzed biosynthesis and secretion
of α-galactosidase A in cultured fibroblasts, and determined enzyme
activity in plasma. It was demonstrated that the proportion of α-ga-
lactosidase A that was secreted by unaffected fibroblasts into the cul-
ture media was significantly less than that of other lysosomal proteins.
In control plasma, α-galactosidase A activity was similar to that of
iduronate-2-sulphatase, however, the molecular form of α-galactosi-
dase in plasma is the mature 46 kDa enzyme and not the high-uptake,
mannose 6-phosphorylated form. Moreover, the authors confirmed that
the mature 46 kDa enzyme, which lacks the mannose-6-phosphate re-
sidue cannot be efficiently endocytosed by affected cells. Using an ar-
tificial in cellulo technique, no complementary functional cross-correc-
tion (degradation of the storage material ceramide trihexoside) in the
Fabry system was observed, whereas cross-correction (glycosami-
noglycan degradation) was confirmed in Hunter fibroblasts.
These findings indicate that in contrast to the situation in Hunter
syndrome, Fabry heterozygotes show clinical manifestation - and that in
vivo, the unaffected cells principally secrete the mature, rather than the
mannose-6-phosphorylated form of α-galactosidase that is able to
complement the activity in the population of cells lacking expression of
the enzyme. An alternative explanation is that compared with idur-
onate-2-sulphatase, α-galactosidase A released by the population of
wild type cells in the mixed population of the female mosaic, is more
susceptible to dephosphorylation by plasma phosphatases. This means
that - by using the term that has been introduced by Dobyns et al. - in
Fabry disease the gene product is operationally cell autonomous, as it
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cannot be readily complemented in the presence of wild type cells [8].
Under these circumstances, in females with α-galactosidase deficiency,
the degree of disease expression with clinical manifestations will be
more exquisitely dependent on the degree of X-inactivation - as un-
ambiguously demonstrated by Echevarria et al. [9]: This group in-
vestigated 65 females with Fabry disease and explored the X-inactiva-
tion profiles in four tissues using DNA methylation analysis. The
authors confirmed that heterozygous female Fabry patients with
skewed X-inactivation profiles differed markedly in the severity of their
clinical manifestations and in a manner that was directly related to
which of the parenteral GLA alleles was most frequently inactivated:
Inactivation of the mutant allele leads to a mild phenotype, and in-
activation of the wild-type GLA allele induces disease with an earlier
onset and worse prognosis [9].
In summary, it can be shown that in Fabry disease heterozygous
females are not simply genetic carriers, but they express the patholo-
gical phenotype to a variable degree, as their plasma mostly contains
46 kDa mature form of the α-galactosidase A that lacking mannose 6-
phosphorylated residues cannot readily be taken up by other cells.
Enzyme replacement therapy, however, is at least partially effective as
the recombinant enzyme preparations consist of the 52 kDa high-uptake
form, containing numerous mannose 6-phosphorylated moieties.
In contrast to Fabry disease, in Hunter syndrome cross-correction of
the metabolic defect takes place as - in comparison with α-galactosidase
A - approximately 10-fold more iduronate-2-sulphatase is present in the
culture medium. Furthermore, this enzyme is highly sialylated, a
property which may maintain a circulating pool preventing receptor-
mediated recapture and antibody recognition [7]. The findings provide
a plausible operational explanation as to why heterozygous females
with Hunter syndrome in general are simple genetic carriers without
any clinical manifestations. Phenotypic expression in females with
Hunter syndrome are exceptions that immediately mandate clarifica-
tion by careful genetic studies (including karyotyping, degree of X-in-
activation, pedigree analysis).
In summary, Fabry disease vividly shows that compared with
Hunter disease, there is variable clinical expression in heterozygous
females, as it is also seen in Danon disease (OMIM 300257), another X-
linked disorders due to mutations in the lysosomal membrane protein
LAMP-2B [10]. Thus as with many X-linked disorders, their pattern of
inheritance cannot be categorised as an X-linked dominant or X-linked
recessive trait. Moreover, it is clear that disease expression depends on
many factors, including mutation, skewed X-inactivation, clonal ex-
pansion and somatic mosaicism. We concur with Dobyns et al., and also
recommend that the terms X-linked recessive and dominant be dis-
continued, and that all such disorders be simply described as showing
‘X-linked inheritance‘ [8].
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